With nothing further, I would now like to turn the call over to Mr. Alan Shortall, Chief Executive Officer of Unilife Corporation. Alan, the floor is yours.Alan Shortall SLIDE 3 Thank you, Todd. Good day, everyone, and thank you for joining us for our fiscal 2011 third quarter conference call. Joining me on today’s call is our CFO, Richard Wieland. The third quarter of fiscal 2011 marked a significant period for Unilife, as we initiated production of the Unifill ® syringe. With this major milestone now completed, we are conducting final product validation procedures and expect to begin initial sales of the Unifill syringe to pharmaceutical companies in July 2011. There has been an exceptional response to-date from a host of the world’s top pharmaceutical and biotechnology companies for the Unifill syringe. We are very happy with the status of current discussions, and look forward to entering into agreements with a number of interested pharmaceutical companies over the coming months. The Unifill syringe has been a great door opener to the top executives and decision makers at these pharmaceutical companies. A key reason for this is that before we came along, virtually everyone believed that integrating safety features into the primary drug container of a prefilled syringe was an impossible task. Having now achieved the impossible with the commercialization of the Unifill syringe, Unilife has established the credibility and proven expertise to serve as a device innovation partner for pharmaceutical companies in other fast-growing and high-value sectors of the drug delivery device market. Increasingly, top pharmaceutical companies are seeking access to highly innovative devices, such as Unifill, that can be customized to meet the specific needs of target biological drugs in their R&D pipeline. These companies are now seeking to work with us to develop additional device solutions that can satisfy their unmet drug delivery requirements.